PHRecommendable#1 in categoryHIGH CONVICTIONPrimary Pick

Mirae Asset Healthcare Fund

Mirae Asset MF · Vrijesh Kasera · benchmarked to Nifty Pharma TRI

Prospera Research Engine v7 · Data as of 24 Aug 2026 · Synced 14 Sept 2026Review date unknown — validation required

Prospera VerdictProspera Recommended

BEATS 2: Broader mandate - hospitals (35%), diagnostics, devices alongside pharma. US tariff on generics hits Nippon harder than Mirae. Max Healthcare + Apollo = domestic HC demand story Nippon cannot access. STW 9 vs 7.

Final Score77.4

1Y Return9.8%

3Y CAGR18.4%

5Y CAGR24.2%

AUM₹8.5K Cr

Expense Ratio0.59%

Eligibility: All gates passed

Prospera Research

Score Breakdown

13 weighted parameters, exactly as configured in the Research Engine — 8 qualitative (analyst-scored) plus 5 quantitative (formula-derived), summing to a final score out of 100.

Momentum (7% weight)8.0/10

3–6M price+flow vs benchmark

Consistency (10% weight)8.0/10

3Y/5Y quartile rank stability

Portfolio Quality (11% weight)9.0/10

PE, concentration, churn

Fund Mgr Quality (12% weight)8.0/10

Philosophy, communication, style drift

Valuation Risk (10% weight)7.0/10

Portfolio PE/PB vs category avg

Sector Tailwinds (9% weight)9.0/10

Policy/macro drivers 12-18M

Downside Protection (8% weight)8.0/10

Max DD, Sortino, bear markets

Outperformance Prob. (8% weight)8.0/10

Analyst 12M alpha probability

Mgr Tenure Score (8% weight)6.0/10

Years managing fund → 1-10 score

AMC Quality Score (6% weight)7.0/10

Research depth, AUM scale, compliance

AUM Trend Score (5% weight)6.0/10

Growing=9, Stable=6, Declining=3

Expense Ratio Score (4% weight)7.0/10

Inverse ER — lower cost = higher score

Thesis Strength (2% weight)8.0/10

Analyst 12-24M thesis conviction

Final Score77.4/100

Prospera Research

Why This Fund

Stance: 12% max allocation

Prospera Research

Analyst Write-Up

A full analyst write-up hasn't been published for this fund yet — only shortlisted funds at the review stage get one. The score breakdown and performance data above are still real and current.

Prospera Research

Risk-Adjusted Performance

3Y Alpha—

5Y Alpha-1.4%

Max Drawdown24.2%

Sharpe (3Y)0.94

Sortino (3Y)1.20

Beta0.82

Alpha Consistency78%

Prospera Research

AMC & Manager Intelligence

Mirae Asset MF

AA — TIER 2

18-analyst research team · Clean — 0 violations

Korean parent (Mirae Asset) provides global research overlay unusual in India. Healthcare thesis by Vrijesh Kasera was prescient. AUM growing at industry-leading pace. Governance best-practice from Korean parent standards.

Vrijesh Kasera

STRONG

6Y tenure · Healthcare Generalist · Confidence 8/10

6Y focused healthcare tenure. First fund manager to allocate 35% to hospitals — prescient call that drove alpha. Growing research team support from Mirae. Watch at Rs15K Cr AUM.